Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients-Reference-Cited by-同舟云学术

Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients

Published:2014-02 Issue:2 Volume:20 Page:160-166
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Venton G.,Crocchiolo R.,Fürst S.,Granata A.,Oudin C.,Faucher C.,Coso D.,Bouabdallah R.,Berger P.,Vey N.,Ladaique P.,Chabannon C.,Merlin M. le,Blaise D.,El-Cheikh J.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference27 articles.

1. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality;Bacigalupo;Haematologica,1992

2. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy;Boeckh;Blood,2004

3. CMV infections after hematopoietic stem cell transplantation;Ljungman;Bone Marrow Transplant,2008

4. Cytomegalovirus in hematopoietic stem cell transplant recipients;Ljungman;Hematol Oncol Clin North Am,2011

5. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients;Ruiz-Camps;Antivir Ther,2011

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience;Transplant Immunology;2024-06

2. A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis;Current Opinion in Infectious Diseases;2023-09-29

3. Evidence supporting the use of therapeutic drug monitoring of ganciclovir in transplantation;Current Opinion in Infectious Diseases;2023-09-19

4. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients;Blood Advances;2023-03-06

5. Cytomegalovirus immunoglobulin therapy for CMV retinitis post hematopoietic stem cell transplantation;European Journal of Ophthalmology;2022-07-11